摘要
目的观察子宫内膜癌组织中微小RNA-23a(miR-23a)与凋亡蛋白酶活化因子-1(APAF-1)的表达变化并分析其临床意义。方法选取2018年5月至2020年5月于我院进行子宫内膜癌切除手术的123例标本为子宫内膜癌组,另选取其癌旁组织为正常组。检测子宫内膜组织中miR-23a与APAF-1的表达情况;分析miR-23a和APAF-1与患者临床病理的关系及二者的相关性,Kaplan-Meier法分析两指标对患者的生存情况的影响。结果与正常组相比,子宫内膜癌组miR-23a的表达升高,APAF-1 mRNA及蛋白表达降低(P<0.05);miR-23a、APAF-1均与临床分期、组织分化程度及肌层浸润显著相关(P<0.05);miR-23a与APAF-1呈显著负相关(P<0.05);Kaplan-Meier曲线显示miR-23a低表达组与APAF-1阳性表达组中的PFS、OS显著高于miR-23a高表达组和APAF-1阴性表达组(P<0.05)。结论子宫内膜癌中miR-23a表达升高,APAF-1降低,二者与子宫内膜癌的发展及患者预后相关,有望成为临床上评估早期患者疾病进展及预后的生物标记物。
Objective To observe the expression changes of micro RNA-23a(miR23a)and apoptotic protease-activating factor-1(APAF-1)in endometrial carcinoma tissues and analyze its clinical significance.Methods 123 specimens of endometrial carcinoma in our hospital from May 2018 to May 2020 were selected as endometrial carcinoma group,and the para cancerous tissue was selected as the normal group.Expression of miR-23a and APAF-1 were examined in endometrial tissues;the relationship between miR-23a and APAF-1 and the clinicopathology of patients and the correlation between the two were analyzed;Kaplan-Meier method was used to analyze the survival of patients with endometrial cancer.Results Compared with the normal group,the expression level of miR-23a in endometrial carcinoma group was significantly increased,the expressions of APAF-1 mRNA and protein decreased significantly(P<0.05);miR-23a and APAF-1 were significantly correlated with clinical stage,histological differentiation and myometrial invasion(P<0.05);Pearson analysis showed that miR-23a was negatively correlated with APAF-1(P<0.05);Kaplan-Meier curves showed that PFS and OS were significantly higher in the miR-23a low-expression group as well as the APAF-1-positive expression group than in the miR-23a highexpression group and the APAF-1-negative expression group(P<0.05).Conclusion The expression level of miR-23a is increased and APAF-1 expression is decreased in endometrial carcinoma,both of which correlate with endometrial cancer progression and patient prognosis,are expected to be biomarkers for clinical assessment of disease progression and prognosis in early-stage patients.
作者
张琼
何素丽
ZHANG Qiong;HE Suli(Department of Obstetrics and Gynecology,Yangzhou University Affiliated Hospital,Yangzhou 225000,China)
出处
《实用医学杂志》
CAS
北大核心
2024年第15期2116-2120,共5页
The Journal of Practical Medicine
基金
江苏省妇幼健康科研项目(编号:F202134)。
